TP53 and hematologic disorder: Importantly, our first-in-human trial of CX-5461 in patients with advanced hematological cancers established on-target efficacy in targeting Pol I transcription and demonstrated single-agent anti-tumor activity in p53 wildtype and p53-mutant hematologic malignancies (Khot et al., 2019).